Shares of Trevena, Inc. (NASDAQ:TRVN) last traded at $2.40. The company’s performance year to date is -59.18%. The 200 day simple moving average is -55.40%. The 200 simple moving average (SMA) is considered a key indicator by traders and market analysts for determining the overall long-term trend. The price level in a market that coincides with the 200 SMA is recognized as a major support when price is above the 200 SMA or resistance when price is below the 200 SMA level.
As per recent filings, Trevena, Inc. (NASDAQ:TRVN) has an insider ownership of 0.40%.
Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania.
Trevena, Inc. (NASDAQ:TRVN) has been storming Wallstreet with solid press release. Recently, the company announced that according to the March 2017 study commissioned by RetailMeNot and conducted by Forrester Consulting, the company’s mobile marketing solutions generate a three-year, risk-adjusted return on investment (ROI) of 4.3x.
The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend. The market is in highly oversold territory. Beware of a trend reversal.
The Exponential Moving Average (EMA) is similar to a simple moving average (average price over a set period) but it utilizes a weighting factor that exponentially declines from the most recent data point (recent prices are weighted higher than oil prices). EMA analysis compares the short term (5 days and 13 days), intermediate term (20 days) and long term (50 days) EMA’s. The respective EMA’s will give bullish signals when trading above trailing EMA’s and below the current price and vice versa. EMA alerts include crossovers (i.e the 5 day EMA crosses above/below the 20 day EMA) and EMA convergencies (5 day EMA equivalent to 13 day EMA). The 5 day EMA 2.73 is higher than the last trade price suggesting a short term bearish pattern building up. Long term, the 50 day EMA 3.46 is also higher than the current trading price depicting a bearish trend overall..
The relative strength index (RSI) is a momentum oscillator that is able to measure the velocity and magnitude of stock price changes. Momentum is calculated as the ratio of positive price changes to negative price changes. The RSI analysis compares the current RSI against neutral(50), oversold (30) and overbought (70) conditions. Alerts will inform you when stocks recede from oversold/overbought levels or breakthrough neutral (50). The current RSI is 22.07 suggesting a bearish price action.
Trevena, Inc. (NASDAQ:TRVN) is all set to announce its earnings on May 04. As per Zack’s analyst ratings, Trevena, Inc. (NASDAQ:TRVN) currently has an average brokerage rating of 1.13. On a scale of 1 to 5, a rating of 1 or 2 would indicate a buy, and a rating of 4 or 5 would signify a sell recommendation. A rating of 3 would indicate a hold on the stock. The consensus target price on (NASDAQ:TRVN) is $10.312 with a high of $15 and a low of $8.
As such, while we believe Trevena, Inc. (NASDAQ:TRVN) represents a compelling growth story exposed to several secularly attractive markets, it would be interesting to see how it fairs for long-term investors.
Trevena, Inc. (NASDAQ:TRVN) today announced the first scientific presentation of positive results from two Phase 3 pivotal efficacy studies of OLINVO(TM) (oliceridine injection), an investigational, next-generation intravenous (IV) opioid analgesic in development for the management of moderate-to-severe acute pain in the hospital and similar settings. The data were highlighted in two poster presentations at the 42 Annual Regional Anesthesiology and Acute Pain Medicine Meeting hosted in San Francisco by the American Society of Regional Anesthesia and Pain Medicine (ASRA). The data showed significant efficacy of OLINVO in managing moderate-to-severe acute pain, and included head-to-head comparisons to IV morphine suggesting that OLINVO could be a valuable new analgesic option for patients at risk of opioid-related adverse events.